{"pmid":32339703,"title":"Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak.","text":["Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak.","J Am Acad Dermatol","Fernandez-Nieto, D","Jimenez-Cauhe, J","Suarez-Valle, A","Moreno-Arrones, O M","Saceda-Corralo, D","Arana-Raja, A","Ortega-Quijano, D","32339703"],"journal":"J Am Acad Dermatol","authors":["Fernandez-Nieto, D","Jimenez-Cauhe, J","Suarez-Valle, A","Moreno-Arrones, O M","Saceda-Corralo, D","Arana-Raja, A","Ortega-Quijano, D"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32339703","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.jaad.2020.04.093","keywords":["sars-cov-2","acro-ischemia","chilblain","erythema multiforme","ischemia","skin","virus"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1665264685592608768,"score":8.574329,"similar":[{"pmid":32330324,"title":"Acral cutaneous lesions in the Time of COVID-19.","text":["Acral cutaneous lesions in the Time of COVID-19.","Coronavirus disease 2019 (COVID-19) has become a pandemic condition, yet little is known about its dermatologic manifestations. We report here on peculiar (perniosis-like) skin lesions, unreported in the previous years, observed in young outpatients visited in our Dermatologic Unit in the last 4 weeks of COVID-19 pandemic (March-April 2020). Similar cases were referred to us in the same period by Pediatricians and Dermatologists from Italy and European countries.","J Eur Acad Dermatol Venereol","Recalcati, S","Barbagallo, T","Frasin, L A","Prestinari, F","Cogliardi, A","Provero, M C","Dainese, E","Vanzati, A","Fantini, F","32330324"],"abstract":["Coronavirus disease 2019 (COVID-19) has become a pandemic condition, yet little is known about its dermatologic manifestations. We report here on peculiar (perniosis-like) skin lesions, unreported in the previous years, observed in young outpatients visited in our Dermatologic Unit in the last 4 weeks of COVID-19 pandemic (March-April 2020). Similar cases were referred to us in the same period by Pediatricians and Dermatologists from Italy and European countries."],"journal":"J Eur Acad Dermatol Venereol","authors":["Recalcati, S","Barbagallo, T","Frasin, L A","Prestinari, F","Cogliardi, A","Provero, M C","Dainese, E","Vanzati, A","Fantini, F"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330324","week":"202017|Apr 20 - Apr 26","doi":"10.1111/jdv.16533","keywords":["covid-19","acral lesions","children","cutaneous manifestations","pediatric population","skin"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Pediatricians","Dermatologists","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"_version_":1664996914780700672,"score":118.886566},{"pmid":32339344,"title":"Vascular skin symptoms in COVID-19: a french observational study.","text":["Vascular skin symptoms in COVID-19: a french observational study.","Coronavirus 19 (COVID-19) was declared as a pandemic viral infection by the World Health organization on March 11(th) 2020. Usual clinical manifestations of COVID-19 infection include fever, fatigue, myalgia, headache, diarrhea, dry cough, dyspnea that may lead to acute respiratory distress syndrome and death (1). Skin symptoms of COVID-19 have been poorly described but may include erythematous rash, urticaria and chicken pox like lesions (2-7). Angiotensin-converting enzyme 2 (ACE2) is a cellular receptor for COVID-19.","J Eur Acad Dermatol Venereol","Bouaziz, J D","Duong, T","Jachiet, M","Velter, C","Lestang, P","Cassius, C","Arsouze, A","Domergue Than Trong, E","Bagot, M","Begon, E","Sulimovic, L","Rybojad, M","32339344"],"abstract":["Coronavirus 19 (COVID-19) was declared as a pandemic viral infection by the World Health organization on March 11(th) 2020. Usual clinical manifestations of COVID-19 infection include fever, fatigue, myalgia, headache, diarrhea, dry cough, dyspnea that may lead to acute respiratory distress syndrome and death (1). Skin symptoms of COVID-19 have been poorly described but may include erythematous rash, urticaria and chicken pox like lesions (2-7). Angiotensin-converting enzyme 2 (ACE2) is a cellular receptor for COVID-19."],"journal":"J Eur Acad Dermatol Venereol","authors":["Bouaziz, J D","Duong, T","Jachiet, M","Velter, C","Lestang, P","Cassius, C","Arsouze, A","Domergue Than Trong, E","Bagot, M","Begon, E","Sulimovic, L","Rybojad, M"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32339344","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/jdv.16544","keywords":["covid-19","chilblain","livedo","purpura","thrombosis","vasculitis"],"locations":["fatigue","myalgia","headache","diarrhea","french"],"countries":["France"],"countries_codes":["FRA|France"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1665264685505576962,"score":93.59537},{"pmid":32253799,"title":"Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine.","text":["Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine.","A severe cutaneous drug reaction resembling acute generalized exanthematous pustulosis resulting from ingestion of hydroxychloroquine has been documented. It is distinguishable by its longer incubation period, more varied morphology with initially urticarial and later targetoid and arcuate plaques, recalcitrance to therapy and longer duration. Given the anticipated surge in the use of hydroxychloroquine due to its reported benefits in those with coronavirus disease 2019, specific recognition of this entity is pivotal. We delineate it as generalized pustular figurate erythema.","Dermatol Ther","Schwartz, Robert A","Janniger, Camila K","32253799"],"abstract":["A severe cutaneous drug reaction resembling acute generalized exanthematous pustulosis resulting from ingestion of hydroxychloroquine has been documented. It is distinguishable by its longer incubation period, more varied morphology with initially urticarial and later targetoid and arcuate plaques, recalcitrance to therapy and longer duration. Given the anticipated surge in the use of hydroxychloroquine due to its reported benefits in those with coronavirus disease 2019, specific recognition of this entity is pivotal. We delineate it as generalized pustular figurate erythema."],"journal":"Dermatol Ther","authors":["Schwartz, Robert A","Janniger, Camila K"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32253799","week":"202015|Apr 06 - Apr 12","doi":"10.1111/dth.13380","keywords":["covid-19","dress syndrome","sars-2","sars-cov-2","stevens-johnson syndrome","sweet syndrome","acute generalized exanthematous pustulosis","coronavirus","drug rash","erythema multiforme","figurate erythema","hydroxychloroquine","toxic epidermal necrolysis","urticaria"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Hydroxychloroquine"],"_version_":1664640769879703552,"score":88.65456},{"pmid":32294262,"title":"Comment on: Cutaneous manifestations in COVID-19: a first perspective. Safety concerns of clinical images and skin biopsies.","text":["Comment on: Cutaneous manifestations in COVID-19: a first perspective. Safety concerns of clinical images and skin biopsies.","We have read with great interest the article: Cutaneous manifestations in COVID-19: a first perspective by Recalcati S.(1) This article is the first report of the cutaneous manifestations in Coronavirus Disease 2019 (COVID-19) patients during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in Lombardy, Italy.","J Eur Acad Dermatol Venereol","Fernandez-Nieto, D","Ortega-Quijano, D","Segurado-Miravalles, G","Pindado-Ortega, C","Prieto-Barrios, M","Jimenez-Cauhe, J","32294262"],"abstract":["We have read with great interest the article: Cutaneous manifestations in COVID-19: a first perspective by Recalcati S.(1) This article is the first report of the cutaneous manifestations in Coronavirus Disease 2019 (COVID-19) patients during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in Lombardy, Italy."],"journal":"J Eur Acad Dermatol Venereol","authors":["Fernandez-Nieto, D","Ortega-Quijano, D","Segurado-Miravalles, G","Pindado-Ortega, C","Prieto-Barrios, M","Jimenez-Cauhe, J"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294262","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jdv.16470","keywords":["covid-19","exanthem","rash","skin","virus"],"source":"PubMed","weight":0,"locations":["Lombardy","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"_version_":1664636192494190592,"score":86.96475},{"pmid":32220276,"title":"[Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia].","text":["[Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia].","Objective: To investigate the clinical and coagulation characteristics of the critical Coronavirus disease 2019 (COVID-19) patients with acro-ischemia in the intensive care unit (ICU). Methods: The retrospective study included 7 critical COVID-19 patients with acro-ischemia in a single center in Wuhan, from Feb 4 to Feb 15, 2020. The clinical and laboratory data before and during the ICU stay were analyzed. Results: The median age of 7 patients was 59 years and 4 of them were men. 3 of them were associated with underlying comorbidities. Fever, cough, dyspnea and diarrhea were common clinical symptoms. All patients had acro-ischemia presentations including finger/toe cyanosis, skin bulla and dry gangrene. D-dimer, fibrinogen and fibrinogen degradation product (FDP) were significantly elevated in most patients. Prothrombin time (PT) were prolonged in 4 patients. D-dimer and FDP levels increased progressively when COVID-2019 exacerbated, and 4 patients were diagnosed with definite disseminated intravascular coagulation (DIC). 6 patients received low molecular weight heparin (LMWH) treatment, after which their D-dimer and FDP decreased, but there was no significant improvement in clinical symptoms. 5 patients died finally and the median time from acro-ischemia to death was 12 days. Conclusions: The existence of hypercoagulation status in critical COVID-2019 patients should be monitored closely, and anticoagulation therapy can be considered in selected patients. More clinical data is needed to investigate the role of anticoagulation in COVID-2019 treatment.","Zhonghua Xue Ye Xue Za Zhi","Zhang, Y","Cao, W","Xiao, M","Li, Y J","Yang, Y","Zhao, J","Zhou, X","Jiang, W","Zhao, Y Q","Zhang, S Y","Li, T S","32220276"],"abstract":["Objective: To investigate the clinical and coagulation characteristics of the critical Coronavirus disease 2019 (COVID-19) patients with acro-ischemia in the intensive care unit (ICU). Methods: The retrospective study included 7 critical COVID-19 patients with acro-ischemia in a single center in Wuhan, from Feb 4 to Feb 15, 2020. The clinical and laboratory data before and during the ICU stay were analyzed. Results: The median age of 7 patients was 59 years and 4 of them were men. 3 of them were associated with underlying comorbidities. Fever, cough, dyspnea and diarrhea were common clinical symptoms. All patients had acro-ischemia presentations including finger/toe cyanosis, skin bulla and dry gangrene. D-dimer, fibrinogen and fibrinogen degradation product (FDP) were significantly elevated in most patients. Prothrombin time (PT) were prolonged in 4 patients. D-dimer and FDP levels increased progressively when COVID-2019 exacerbated, and 4 patients were diagnosed with definite disseminated intravascular coagulation (DIC). 6 patients received low molecular weight heparin (LMWH) treatment, after which their D-dimer and FDP decreased, but there was no significant improvement in clinical symptoms. 5 patients died finally and the median time from acro-ischemia to death was 12 days. Conclusions: The existence of hypercoagulation status in critical COVID-2019 patients should be monitored closely, and anticoagulation therapy can be considered in selected patients. More clinical data is needed to investigate the role of anticoagulation in COVID-2019 treatment."],"journal":"Zhonghua Xue Ye Xue Za Zhi","authors":["Zhang, Y","Cao, W","Xiao, M","Li, Y J","Yang, Y","Zhao, J","Zhou, X","Jiang, W","Zhao, Y Q","Zhang, S Y","Li, T S"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32220276","week":"202014|Mar 30 - Apr 05","doi":"10.3760/cma.j.issn.0253-2727.2020.0006","keywords":["anticoagulation therapy","critical, covid-2019, hypercoagulation status"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Heparin, Low-Molecular-Weight"],"_version_":1664638629667930113,"score":73.05465}]}